Moberg Pharma (MOB) Aktievy
Moberg Pharma AB (publ) är ett läkemedelsföretag som utvecklar och kommersialiserar medicinska produkter främst i Sverige. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 5/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
MOB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Moberg Pharma AB (publ) Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | SEK 11.08 |
| 52 veckors högsta | SEK 14.12 |
| 52 veckors lägsta | SEK 7.53 |
| Beta | 1.07 |
| 1 månads förändring | 19.78% |
| 3 månaders förändring | 3.55% |
| 1 års förändring | 29.59% |
| 3 års förändring | 52.83% |
| 5 års förändring | -82.44% |
| Förändring sedan börsintroduktionen | -96.14% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 14
MOB: Expanded Licensing And Upcoming Launches Will Drive Future Upside Potential
Analysts have raised their price target for Moberg Pharma from SEK 14 to SEK 16, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of the change. What's in the News for Moberg Pharma The first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare's brand, which creates a clearer timetable for launch preparations and marketing activities in those markets.Uppdatering av berättelse • Jun 24
MOB: Expanded Licensing Network Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Moberg Pharma steady at SEK 14.0 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E despite the updated price target data. What’s in the News for Moberg Pharma The first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare's brand, with commercial production and launch activities planned ahead of the high season, source: company key developments.Analysartikel • Jun 18
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent updates
Uppdatering av berättelse • Aug 14
MOB: Expanded Licensing And Upcoming Launches Will Drive Future Upside Potential
Analysts have raised their price target for Moberg Pharma from SEK 14 to SEK 16, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of the change. What's in the News for Moberg Pharma The first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare's brand, which creates a clearer timetable for launch preparations and marketing activities in those markets.Uppdatering av berättelse • Jun 24
MOB: Expanded Licensing Network Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Moberg Pharma steady at SEK 14.0 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E despite the updated price target data. What’s in the News for Moberg Pharma The first European countries have approved the rebranding of MOB-015 (Terclara) to Karo Healthcare's brand, with commercial production and launch activities planned ahead of the high season, source: company key developments.Analysartikel • Jun 18
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Uppdatering av berättelse • Jun 02
MOB: Dual Terbinafine Supply And Expanded Licensing Will Support Future Re Rating Potential
Analysts have adjusted their price target on Moberg Pharma to SEK14.00 from SEK13, reflecting updated assumptions around revenue growth, profit margins, discount rate and future P/E. These changes collectively reshape their view of the stock’s risk and reward profile.Uppdatering av berättelse • Apr 21
MOB: Dual Terbinafine Suppliers And Broader Mandate Will Support Future Re Rating Potential
Analysts now hold the fair value estimate for Moberg Pharma steady at SEK 13.0, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that the recent review has not altered their SEK-based price target framework. What's in the News Moberg Pharma plans to propose an amendment to its articles of association at the AGM scheduled for 21 May 2026.Uppdatering av berättelse • Apr 06
MOB: Dual Terbinafine Sourcing Will Support Future Re Rating Potential
Analysts have reaffirmed their price target for Moberg Pharma at SEK 13.0 per share, citing unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Regulators have approved an additional supplier of terbinafine for MOB-015, Moberg Pharma's drug for nail fungus, after a process that started in April 2024 (Key Developments).Uppdatering av berättelse • Mar 23
MOB: Dual Supplier Approval Will Support Future Re Rating Potential
Analysts have maintained their SEK fair value estimate for Moberg Pharma at SEK 13.0, with unchanged assumptions for the discount rate, revenue growth, profit margin and future P/E. This suggests their view on the company’s risk and earnings outlook remains essentially intact.Uppdatering av berättelse • Mar 07
MOB: Stable Assumptions And Profitability Outlook Will Support Future Re Rating
Analysts have maintained their SEK 13.0 price target for Moberg Pharma, reflecting unchanged views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Valuation Changes Fair Value: SEK 13.0 is unchanged, with only rounding differences between the previous SEK 13 and the current SEK 13.0 figure.Uppdatering av berättelse • Feb 21
MOB: Higher Profitability Assumptions Will Support Re Rating Of Undervalued Shares
Analysts have adjusted their price target on Moberg Pharma to SEK 13.0. This reflects updated views on revenue growth, profit margin and a lower future P/E assumption. Valuation Changes Fair Value: SEK 13.0 is unchanged, indicating no revision to the overall price estimate.Uppdatering av berättelse • Feb 05
MOB: Undervalued Shares Will Rely On Stable Assumptions To Re-Rate
Analysts have kept their price target for Moberg Pharma steady at SEK 13.00. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.Uppdatering av berättelse • Jan 22
MOB: Europe Licensing Agreement Will Support Future Share Price Upside
Analysts have kept their price target for Moberg Pharma steady at SEK 13.0. This reflects unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E despite the latest review of their model inputs. What's in the News Karo Healthcare AB and Moberg Pharma AB have signed an exclusive licensing agreement for the commercialisation of MOB-015 in 19 European markets, covering a population of about 500 million people (Key Developments).Uppdatering av berättelse • Jan 08
MOB: Europe Licensing Agreement Will Support Strong Future Share Price Upside
Analysts have maintained their price target on Moberg Pharma at SEK 13.0, with unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This indicates their core view on the stock remains intact for now.Uppdatering av berättelse • Dec 16
MOB: Exclusive European Licensing Deal Will Drive Strong Future Share Upside
Analysts have marginally adjusted their price target on Moberg Pharma, reiterating a fair value of SEK 13.0 per share as they maintain their assumptions for discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News Karo Healthcare AB signs an exclusive licensing agreement with Moberg Pharma for the commercialisation of MOB-015 across 19 European markets, including all major EU countries and the United Kingdom, ensuring a coordinated launch under the Lamisil brand (Company announcement) The licensing deal grants Karo responsibility for marketing, distribution, and sales in 11 countries where MOB-015 is already approved but not yet launched, accelerating the product’s European rollout (Company announcement) MOB-015, a new topical terbinafine formulation, demonstrates mycological cure rates of 76 percent in registration studies, delivering efficacy on par with oral treatment and addressing historical challenges in penetrating the nail (Company announcement) The agreement provides Moberg Pharma with access to a total addressable population of about 500 million people in Europe, significantly expanding the commercial potential of MOB-015 (Company announcement) Valuation Changes Fair Value: Unchanged at SEK 13.0 per share, reflecting a stable outlook for Moberg Pharma’s intrinsic valuation.Uppdatering av berättelse • Dec 02
MOB: Exclusive Licensing Deal Will Unlock Major European Market Launches
Analysts have maintained their price target for Moberg Pharma at SEK 13.00. This reflects continued confidence in the company's earnings outlook and growth potential.Uppdatering av berättelse • Nov 18
MOB: Licensing Agreement Will Drive Expansion Across Europe This Year
Analysts have raised their price target for Moberg Pharma from SEK 11 to SEK 13. This change reflects updated forecasts that consider notable shifts in anticipated revenue growth, profitability, and market conditions.Analysartikel • Nov 07
We're Not Worried About Moberg Pharma's (STO:MOB) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analysartikel • May 16
Shareholders Will Probably Hold Off On Increasing Moberg Pharma AB (publ)'s (STO:MOB) CEO Compensation For The Time Being
Key Insights Moberg Pharma's Annual General Meeting to take place on 22nd of May Total pay for CEO Anna Ljung includes...
Ny berättelse • Apr 13
Norway Expansion And EU Approvals Will Strengthen Future Position
Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy.Analysartikel • Feb 12
Companies Like Moberg Pharma (STO:MOB) Can Afford To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Sep 14
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysartikel • May 08
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Moberg Pharma to hold its Annual General Meeting on 14th of May Salary of kr1.99m is part of CEO Anna...Analysartikel • Nov 16
Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysartikel • Jan 17
Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analysartikel • Dec 03
Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...Aktieägarnas avkastning
| MOB | SE Pharmaceuticals | SE Marknad | |
|---|---|---|---|
| 7D | 10.9% | 1.5% | -1.0% |
| 1Y | 29.6% | -14.4% | 12.4% |
Avkastning vs industri: MOB översteg Swedish Pharmaceuticals branschen som gav -14.4 % under det senaste året.
Avkastning vs Marknaden: MOB översteg Swedish marknaden som gav 12.4 % under det senaste året.
Prisvolatilitet
| MOB volatility | |
|---|---|
| MOB Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.1% |
Stabil aktiekurs: MOB har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Swedish.
Volatilitet över tid: MOB s veckovolatilitet ( 7% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2006 | 5 | Anna Ljung | www.mobergpharma.se |
Moberg Pharma AB (publ) är ett läkemedelsföretag som utvecklar och kommersialiserar medicinska produkter främst i Sverige. Bolaget erbjuder MOB-015 för behandling av nagelsvamp under varumärket Terclara. Bolaget hette tidigare Moberg Derma AB (publ) och bytte namn till Moberg Pharma AB (publ) i maj 2013.
Moberg Pharma AB (publ) Sammanfattning av grunderna
| MOB grundläggande statistik | |
|---|---|
| Börsvärde | SEK 520.77m |
| Vinst(TTM) | -SEK 21.62m |
| Intäkter(TTM) | SEK 16.76m |
31.1x
P/S-förhållande-24.1x
P/E-förhållandeÄr MOB övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| MOB resultaträkning (TTM) | |
|---|---|
| Intäkter | SEK 16.76m |
| Kostnad för intäkter | SEK 6.32m |
| Bruttovinst | SEK 10.44m |
| Övriga kostnader | SEK 32.06m |
| Intäkter | -SEK 21.62m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
Nov 12, 2026
| Vinst per aktie (EPS) | -0.46 |
| Bruttomarginal | 62.31% |
| Nettovinstmarginal | -128.96% |
| Skuld/egenkapitalförhållande | 0% |
Hur har MOB utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/16 09:24 |
| Aktiekurs vid dagens slut | 2026/08/14 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Moberg Pharma AB (publ) bevakas av 4 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Klas Pyk | Nordea Markets |
| Mats Hyttinge | Redeye |